羟基红花黄色素A的药代动力学及生物药剂学研究进展  

Pharmacokinetics and biopharmaceutics of hydroxysafflor yellow A: research advances

作　　者：马冠男[1] 喻芳邻[2] 张慧[2] 李志平[2] 梅兴国[2] 

机构地区：[1]武汉工程大学化工与制药学院,武汉430073 [2]军事医学科学院毒物药物研究所,北京100850

出　　处：《国际药学研究杂志》2014年第2期195-199,220,共6页Journal of International Pharmaceutical Research

摘　　要：羟基红花黄色素A(HSYA)是红花的主要活性成分,具有活血化瘀的功效,临床用于心脑血管疾病的治疗。由于HSYA生物利用度低,限制了其口服制剂的开发与应用。近年来,HSYA的生物药剂学研究取得了很大进展,本文着重从HSYA理化性质、药代动力学特征、增加HSYA口服吸收的策略和制剂研究4个方面综述HSYA的研究进展,为相关研究提供参考。Hydrosafflor yellow A （ HSYA）, the main active ingredient of the safflower plant （ Carthamus tinctorius L. ）, has the effect of activating circulation to remove blood stasis, and is usually used to treat cardiovascular and cerebrovascular diseases clini- cally. However, it is difficult to develop its oral dosage forms due to its low bioavailability. In recent years, studies on the biopharmaceutics of HSYA have made significant progress. This paper reviews physic-chemical properties, pharmacokinetics, strategies for promoting bioavailability and progress in pharmaceutics of HSYA, aiming to provide reference for related studies.

关 键 词：羟基红花黄色素A 药代动力学 口服吸收 口服制剂 

分 类 号：R945[医药卫生—微生物与生化药学] R969.1[医药卫生—药剂学]